ADC Therapeutics to Host Second Quarter 2024 Financial Results Conference Call on August 6, 2024
July 30 2024 - 7:15AM
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader
and pioneer in the field of antibody drug conjugates (ADCs), today
announced that it will host a conference call and live webcast on
Tuesday, August 6, 2024, at 8:30 a.m. EDT to report financial
results for the second quarter 2024 and provide operational
updates.
To access the conference call, please register
here. Registrants will receive the dial-in number and unique PIN.
It is recommended that you join 10 minutes before the event, though
you may pre-register at any time. A live webcast of the call will
be available under “Events and Presentations” in the Investors
section of the ADC Therapeutics website at ir.adctherapeutics.com.
The archived webcast will be available for 30 days following the
call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London and New Jersey. For more information,
please visit https://www.adctherapeutics.com/ and follow the
Company on LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. In some cases you can identify
forward-looking statements by terminology such as “may”, “will”,
“should”, “would”, “expect”, “intend”, “plan”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “seem”, “seek”,
“future”, “continue”, or “appear” or the negative of these terms or
similar expressions, although not all forward-looking statements
contain these identifying words. Forward-looking statements are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to: the success
of the Company’s updated corporate strategy including operating
efficiencies, capital deployment and portfolio prioritization; the
Company’s ability to achieve the decrease in total operating
expenses for 2024, the expected cash runway into mid-2026, the
effectiveness of the new commercial go-to-market strategy,
competition from new technologies, and the Company’s ability to
grow ZYNLONTA® revenue in the United States; Swedish Orphan
Biovitrum AB (Sobi®) ability to successfully commercialize
ZYNLONTA® in the European Economic Area and market acceptance,
adequate reimbursement coverage, and future revenue from the same;
approval by the NMPA of the BLA for ZYNLONTA® in China submitted by
Overland ADCT BioPharma and future revenue from the same, our
strategic partners’, including Mitsubishi Tanabe Pharma
Corporation, ability to obtain regulatory approval for ZYNLONTA® in
foreign jurisdictions, and the timing and amount of future revenue
and payments to us from such partnerships; the timing and future
success from the University of Miami’s IITs in FL and MZL; the
timing and results of the Company’s or its partners’ clinical
trials including LOTIS 5 and 7, ADCT 601 and 602 as well as the
Company’s early-stage pipeline research projects, actions by the
FDA or foreign regulatory authorities with respect to the Company’s
products or product candidates; projected revenue and expenses; the
Company’s indebtedness, including Healthcare Royalty Management and
Oaktree and Blue Owl facilities, and the restrictions imposed on
the Company’s activities by such indebtedness, the ability to repay
such indebtedness and the significant cash required to service such
indebtedness; and the Company’s ability to obtain financial and
other resources for its research, development, clinical, and
commercial activities. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the “Risk Factors” section of the Company's Annual
Report on Form 20-F and in the Company's other periodic reports and
filings with the Securities and Exchange Commission. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance, achievements or
prospects to be materially different from any future results,
performance, achievements or prospects expressed in or implied by
such forward-looking statements. The Company cautions investors not
to place undue reliance on the forward-looking statements contained
in this document. The Company undertakes no obligation to revise or
update these forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by law.
CONTACTS:
InvestorsMarcy GrahamADC
TherapeuticsMarcy.Graham@adctherapeutics.com+1 650-667-6450
MediaNicole RileyADC
TherapeuticsNicole.Riley@adctherapeutics.com+1 862-926-9040
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Oct 2024 to Nov 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Nov 2023 to Nov 2024